These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8447285)

  • 1. Granulomatous inflammation in bladder wash specimens after intravesical bacillus Calmette-Guerin therapy for transitional cell carcinoma of the bladder.
    Betz SA; See WA; Cohen MB
    Am J Clin Pathol; 1993 Mar; 99(3):244-8. PubMed ID: 8447285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer.
    Oates RD; Stilmant MM; Freedlund MC; Siroky MB
    J Urol; 1988 Oct; 140(4):751-4. PubMed ID: 3418796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.
    Lage JM; Bauer WC; Kelley DR; Ratliff TL; Catalona WJ
    J Urol; 1986 May; 135(5):916-9. PubMed ID: 3959240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
    Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma.
    Marans HY; Bekirov HM
    J Urol; 1987 Jan; 137(1):111-2. PubMed ID: 3795348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations.
    Mukamel E; Konichezky M; Engelstein D; Cytron S; Abramovici A; Servadio C
    J Urol; 1990 Dec; 144(6):1399-400. PubMed ID: 2231934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serious complications of intravesical bacillus Calmette-Guerin therapy in patients with bladder cancer].
    Kudo S; Tsushima N; Sawada Y; Saito F; Motomura F; Takashima T; Kogawa T; Suzuki T; Kurotaki H; Masumori J
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1594-602. PubMed ID: 1770698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severely contracted bladder following intravesical bacillus Calmette-Guérin therapy].
    Yoshimura K; Saiki S; Kuroda M; Kiyohara H; Kotake T
    Nihon Hinyokika Gakkai Zasshi; 1988 Nov; 79(11):1848-51. PubMed ID: 3216568
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytological, histological, and clinical correlations in intravesical Bacillus Calmette-Guerin immunotherapy.
    Bhan R; Pisharodi LR; Gudlaugsson E; Bedrossian C
    Ann Diagn Pathol; 1998 Feb; 2(1):55-60. PubMed ID: 9845722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
    Yates J; Stein B
    Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report.
    Merguerian PA; Donahue L; Cockett AT
    J Urol; 1987 Feb; 137(2):216-9. PubMed ID: 3492613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guérin-treated superficial bladder cancer: correlation of morphology with immunophenotyping.
    Leong AS; Wannakrairot P; Jose J; Milios J
    J Pathol; 1990 Sep; 162(1):35-41. PubMed ID: 2231190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal complications of intravesical bacillus Calmette-Guérin therapy.
    Modesto A; Marty L; Suc JM; Kleinknecht D; de Frémont JF; Marsepoil T; Veyssier P
    Am J Nephrol; 1991; 11(6):501-4. PubMed ID: 1819218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of bacillus Calmette-Guerin intravesical therapy on the diagnostic efficacy of The Paris System for Reporting Urinary Cytology in patients with high-grade bladder cancer.
    Hermans J; Jokisch F; Volz Y; Eismann L; Pfitzinger P; Ebner B; Weinhold P; Schlenker B; Stief CG; Tritschler S; Schulz GB
    Cancer Cytopathol; 2022 Apr; 130(4):294-302. PubMed ID: 34919338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.